

CYCLODESIPEPTIDE AND DIOXOMORPHOLINE DERIVATIVES ISOLATED FROM THE INSECT- BODY PORTION OF THE FUNGUS *CORDYCEPS* *CICADA*

Yuh-Chi Kuo^{1,2}, Lie-Chwen Lin¹, Ming-Jaw Don¹, Hui-Fen Liao¹,
Yu-ping Tsai¹, Gene-Hsiang Lee³ and Cheng-Jen Chou¹

¹*National Research Institute of Chinese Medicine,*

²*Institute of Life Science, Fu-Jen University,*

³*Instrumentation Center, College of Science, National Taiwan University*

Taipei, Taiwan

(Received 19th September 2002, revised Ms received 4th October 2002, accepted 11th October 2002)

Seven compounds have been isolated from the methanol extract of the insect-body portions of Chan-hua, and namely ergosterol (**1**), ergosterol peroxide (**2**), bassiatin (**3**), bassiatin A (**4**), beauvericin (**5**), beauvericin A (**6**), and beauvericin B (**7**). The structures of **1**, **2** and **7** were determined by spectral analyses and by comparison with existing data from literatures. Compounds **3**, **4**, **5** and **6** were elucidated by spectral analysis and further confirmed by X-ray crystallography. Among them, three cyclodesipeptides (**5**, **6** and **7**) and two dioxomorpholines (**3**, **4**) derivatives were not previously reported from Chan-hua. Bassiatin A is first isolated from nature.

Key words: *Cordyceps cicadae*, Fungi, Sterol, Cyclodesipeptide, Dioxomorpholine.

INTRODUCTION

Cordyceps cicadae Shing is a parasitic fungus on the larvae of *Cicada flammata* Dist. Both the ascocarps and the insect-body portions are named Chan-hua, and have been used as a drug for childhood convulsion, palpitation, and sedation.¹ In the previous work, there have been a considerable number of papers on the antitumor activity of various polysaccharides in Chan-hua.²⁻⁷ However, there has been a relative scarcity of papers on the immunopharmacological activity of the ascocarps and the insect-body portion of Chan-hua. In the course of our search for physiologically active substances in nature, we found that methanol extract of the insect-body portion of Chan-hua

Correspondence to: Cheng-Jen Chou, National Research Institute of Chinese Medicine, Tel: 02-28201999 ext. 7101, Fax: 02-28264276, E-mail: choucj@cma23.nricm.edu.tw

suppressed proliferation in human mononuclear cells (HMNC) activated by phytohemagglutinin (PHA). The inhibitory activity of the extract was concentration dependent. The IC_{50} of the extract on PHA-treated HMNC was 32.5 $\mu\text{g/ml}$. Similarly, interleukin-2 (IL-2) in activated HMNC was also inhibition by the treatment of the extract. The inhibition of IL-2 was concentration dependent.⁸ This observation led us to investigate the potential biologically active substances of Chan-hua. In the present paper, we describe the extraction, isolation, purification and identification of three cyclodesipeptide and two dioxo-morpholine derivatives. They were not previously reported from this fungus, namely one novel substance, bassiatin A (4), as well as two known sterols.

RESULTS AND DISCUSSION

The methanol extract of the insect-body portions of *C. cicadae* was partitioned between water and ethyl acetate. Column chromatography of the ethyl acetate soluble fraction gave seven compounds. They are ergosterol (1),⁹ ergosterol peroxide (2),^{10,11} bassiatin (3),¹² bassiatin A (4), beauvericin (5),¹³ beauvericin A (6)¹³ and beauvericin B (7).¹³ The structures of these compounds, except 4, were identified by the spectral analyses and by comparison with existing data from the literatures. Compounds 3, 5 and 6 were further confirmed by X-ray crystallographic analysis. The novel substance 4, was elucidated by the spectral analyses and confirmed by X-ray crystallographic analysis. ORTEP




Fig. 1. Structures isolated from *Cordyceps cicadae*




Fig. 2. Perspective structures of bassiatin (3), bassiatin A (4), beauvericin (5), and beauvericin A (6) [atom numbering of this figure does not correspond to the line drawing of structures]

drawing of 3, 4, 5 and 6 were shown in Fig. 2.

Compound 4 was obtained as colorless crystals. The molecular formula of 4 assigned as $C_{16}H_{21}NO_3$ by ^{13}C NMR and DEPT, as well as EI-mass spectrum. As cited in Table 1, the ^{13}C NMR and DEPT shown two carbonyl carbons at δ 167.3 and 165.9, suggesting that these two carbons were connected oxygen and/or nitrogen. The 1H NMR shown the signals of an oxymethine proton at δ 3.06 (*d*, $J = 1.9$ Hz), a sp^3 methine proton at δ 4.39 (*t*, $J = 4.5$ Hz) and one *N*-methyl proton at δ 3.03 (*s*). On the basis of above data, 4 suggested having a skeleton of *N*-methyl-dioxomorpholine. Five aromatic protons at δ 7.28-7.31 (3H, *m*), 7.09 - 7.13 (2H, *m*) were correlated to the carbon signals at δ 129.2, 128.2 and 129.8, respectively, in its C-H COSY spectrum, and one quaternary carbon at δ 134.1 was observed in ^{13}C NMR and DEPT, indicating the presence of a non-substitute benzyl group. Furthermore, the proton signals at δ 3.06 (1H), 1.98 (1H), 1.20 (2H), 0.65 (3H) and 0.71 (3H) were correlated to the carbon signals at

Table 1. ^{13}C and ^1H NMR spectral data of **3** and **4** in CDCl_3 ^a

Compound					
3			4		
Atom	δC	δH	Atom	δC	δH
2	167.2 (<i>s</i>)		2	167.3 (<i>s</i>)	
3	62.7 (<i>d</i>)	4.38 (<i>t</i> , <i>J</i> , 43 Hz)	3	62.7 (<i>d</i>)	4.39 (<i>t</i> , <i>J</i> , 4.5 Hz)
5	165.5 (<i>s</i>)		5	165.9 (<i>s</i>)	
6	81.2 (<i>d</i>)	2.99 (<i>d</i> , <i>J</i> , 2.1 Hz)	6	79.0 (<i>d</i>)	3.06 (<i>d</i> , <i>J</i> , 1.9 Hz)
7	29.6 (<i>d</i>)	2.28 (<i>m</i>)	7	36.1 (<i>d</i>)	1.98 (<i>m</i>)
8	18.5 (<i>q</i>)	0.82 (<i>d</i> , <i>J</i> , 7.0 Hz)	8	25.4 (<i>t</i>)	1.20 (<i>m</i>)
9	15.1 (<i>q</i>)	0.74 (<i>d</i> , <i>J</i> , 6.8 Hz)	9	11.5 (<i>q</i>)	0.65 (<i>t</i> , <i>J</i> , 7.3)
10	37.1 (<i>t</i>)	3.26 (<i>dd</i> , <i>J</i> , 4.1, 14.0 Hz)	10	13.3 (<i>q</i>)	0.71 (<i>d</i> , <i>J</i> , 6.9 Hz)
		3.16 (<i>dd</i> , <i>J</i> , 4.4, 14.0 Hz)	11	37.0 (<i>t</i>)	3.14 (<i>dd</i> , <i>J</i> , 4.6, 13.9 Hz)
11	134.1 (<i>s</i>)				3.26 (<i>dd</i> , <i>J</i> , 4.0, 13.9 Hz)
12, 16	129.7 (<i>d</i>)	7.09 ~ 7.12 (<i>m</i>)	12	134.1 (<i>s</i>)	
13, 15	129.2 (<i>d</i>)	7.29 ~ 7.34 (<i>m</i>)	13, 17	129.8 (<i>d</i>)	7.09 ~ 7.13 (<i>m</i>)
14	128.2 (<i>d</i>)	7.29 ~ 7.34 (<i>m</i>)	14, 16	129.2 (<i>d</i>)	7.28 ~ 7.31 (<i>m</i>)
N-CH ₃	32.4(<i>q</i>)	3.00 (<i>s</i>)	15	128.2 (<i>d</i>)	7.28 ~ 7.31 (<i>m</i>)
			N-CH ₃	32.4 (<i>q</i>)	3.03 (<i>s</i>)

^a Assignments were based on ^{13}C -DEPT, ^{13}C - ^1H COSY and ^1H - ^1H COSY spectra.

δ 79.0, 36.1, 25.4, 11.5 and 13.3, respectively, in its C-H COSY spectrum. These data together with two spin coupling systems, HC-6/HC-7/H₂C-8/H₃C-9 and HC-7/H₃C-10, were obtained in the ^1H - ^1H COSY spectrum, indicating the presence of a 1-methylpropyl moiety in the structure of **4**. Comparison of the ^1H and ^{13}C spectra data of **4** with those of **3**, except the 1-methylethyl moiety is re-placed by the 1-methylpropyl moiety located at C-6 position, were shown similarities. On the basis of above analyses, the structure of **4** was elucidated as 4-methyl-6-(1-methylpropyl)-3-phenylmethyl-1,4-perhydrooxazine-2,5-dione.

The relative stereochemistry of **4** was determined by X-ray crystallographic analysis. A single crystal having an approximate dimension of 0.40 × 0.25 × 0.10 mm was obtained from methanol-water system and used for X-ray crystallographic analysis. An ORTEP drawing of the molecular structure of **4** is shown in Fig. 2. It indicated that the relative stereochemistry at C-3 and C-6 could be either S/R or R/S. Comparing the optical rotations of **4** ($[\alpha]_{\text{D}} + 187.5^\circ$ (c 0.038, dichloromethane)) with that of bassiatin [(3S, 6R)-4-methyl-6-(1-methylethyl)-3-phenylmethyl-1,4-perhydrooxazine-2,5-dione] ($[\alpha]_{\text{D}} + 181.05^\circ$ (c 0.024, chloroform)) and other three isomer - (3R, 6S)-, (3R, 6R)-, (3S, 6S)- compounds.¹² The structure of **4** was determined to be (3S, 6R)-4-methyl-6-(1-methylpropyl)-3-phenylmethyl-1,4-perhydrooxazine-2,5-dione, and named as bassiatin A.

In the ^1H NMR spectrum of **4**, the signal at δ 3.06 assigned to H-6 is unusually in high field as an oxymethine proton neighboring to the 5-carbonyl group. This phenomenon is similar to the proton signal displayed at δ 2.99 of H-6 of bassiatin.² Therefore, judging from the conformation of **4**, the unusual chemical shift of H-6 can be attributed to the strong shielding effect from the benzyl group at C-3.

EXPERIMENTAL

General Experiment Procedures

Melting points were determined with a Yanaco MP-13 micro-melting point apparatus and are uncorrected. IR spectra were obtained as KBr pellets on a Nicolet Avatar 320 FT-IR spectrometer. Optical rotations were measured on a JASCO DIP-370 polarimeter. HRFABMS spectra were recorded in the positive ion mode on a JEOL JMS-HX 110 spectrometer. EIMS spectra were recorded on a Finnigan GCQ GC/MS spectrometer. ^1H , ^{13}C -, and 2D-NMR spectra were recorded on a Bruker ACP-300 spectrometer and a Varian INOVA 500MHz NMR spectrometer. Chemical shifts are shown in δ values (ppm) with deuterated solvents as internal standard. Column chromatography was performed on silica gel 60 (70 ~ 230 mesh, Merck) using a solvent mixture system of ethyl acetate and hexane. HPLC was performed on a preparative reverse phase column and eluted with water-methanol system.

Materials

Cordyceps cicadae (Chan-hua) was purchased from a Chinese medicinal store in Taipei, and identified by Dr. Tun-Tschu Chang of the Division of Forest Protection, Taiwan Forestry Research Institute. A voucher specimen (No. TFR1A46) was deposited in the herbarium of Taiwan Forestry Research Institute, Taipei, Taiwan.

Extraction and Isolation

The dried Chan-hua (fungus: *C. cicadae*) was divided into two portions (the ascocarps and the insect-body). The insect-body of Chan-hua (9.7 Kg) was extracted with methanol at 60 °C over night for three times. The extracts were filtered and vacuum evaporated. The concentrate (1.5 Kg) was suspended in 3L distilled water and partitioned between ethyl acetate and water (1:1 v/v) to give ethyl acetate, water and suspended fractions. Ethyl acetate soluble fraction (535 g) was carried out on silica gel column chromatography with a gradient of ethyl acetate in hexane, and fourteen fractions (1-14) were collected. The fractions were collected in 450 mL portions and pooled according to their TLC profile in hexane-ethyl acetate (90:10, or 80:20 v/v). Fraction 5 was dissolved in methanol and gave crystalline ergosterol (**1**). Fraction 6 was further purified by silica gel MPLC (ethyl acetate gradient in hexane) to give ergosterol peroxide (**2**). After chromatographic separation of fraction 8 on silica gel MPLC (ethyl acetate gradient in hexane), sub-fraction (8-4) was further purified by preparative HPLC with Cosmosil 5C₁₈-AR-II column (20 × 250 mm) using a gradient of methanol in water system to give bassiatin (**3**) and bassiatin A (**4**). Fraction 10 was separated and purified as above treatment to afford beauvericin (**5**), beauvericin A (**6**) and beauvericin B (**7**).

Ergosterol (3 β -hydroxyergosta-5, 7, 22-triene) (1) ⁹

Colorless plates; mp 150-152°C; IR (KBr) ν max cm^{-1} 3420, 2880, 1650, 1460, 1390, 1380, 1060, 1040; ¹H NMR (CDCl_3): δ 3.62 (1H, *m*, H-3), 5.55 (1H, *m*, H-6), 5.35 (1H, *m*, H-7), 0.61 (3H, *s*, CH_3 -18), 0.92 (3H, *s*, CH_3 -19), 1.01 (3H, *d*, $J = 6.6\text{Hz}$, CH_3 -21), 5.18 (1H, *m*, H-22), 5.18 (1H, *m*, H-23), 0.78 (3H, *d*, $J = 6.8\text{Hz}$, CH_3 -26), 0.82 (3H, *d*, $J = 6.8\text{Hz}$, CH_3 -27), 0.90 (3H, *d*, $J = 6.8\text{Hz}$, CH_3 -28); ¹³C NMR (CDCl_3): δ 38.4 (*t*, C-1), 32.0 (*t*, C-2), 70.5 (*d*, C-3), 40.8 (*t*, C-4), 141.3 (*s*, C-5), 119.6 (*d*, C-6), 116.3 (*d*, C-7), 139.8 (*s*, C-8), 46.3 (*d*, C-9), 37.0 (*s*, C-10), 21.1 (*t*, C-11), 39.1 (*t*, C-12), 42.8 (*s*, C-13), 54.6 (*d*, C-14), 23.0 (*t*, C-15), 28.7 (*t*, C-16), 55.7 (*d*, C-17), 12.0 (*q*, C-18), 16.3 (*q*, C-19), 40.4 (*d*, C-20), 19.6 (*q*, C-21), 132.0 (*d*, C-22), 135.6 (*d*, C-23), 42.8 (*d*, C-24), 33.1 (*d*, C-25), 19.9 (*q*, C-26), 21.1 (*q*, C-27), 17.6 (*q*, C-28); EIMS: m/z 396 $[\text{M}]^+$.

Ergosterol peroxide (3 β -hydroxy-5, 8-epidioxyergosta-6, 22-diene) (2) ^{10,11}

Colorless needles; mp 180-182 °C; ¹H NMR (CDCl_3): δ 3.94 (1H, *m*, H-3), 6.20 (1H, *d*, $J = 8.4\text{Hz}$, H-6), 6.47 (1H, *d*, $J = 8.5\text{Hz}$, H-7), 0.79 (3H, *s*, CH_3 -18), 0.86 (3H, *s*, CH_3 -19), 0.97 (3H, *d*, $J = 6.5\text{Hz}$, CH_3 -21), 5.20 (1H, *dd*, $J = 7.5, 15.4\text{Hz}$, H-22), 5.11 (1H, *dd*, $J = 8.5, 15.4\text{Hz}$, H-23), 0.79 (3H, *d*, $J = 6.7\text{Hz}$, CH_3 -26), 0.80 (3H, *d*, $J = 6.6\text{Hz}$, CH_3 -27), 0.88 (3H, *d*, $J = 6.5\text{Hz}$, CH_3 -28); ¹³C NMR (CDCl_3): δ 34.7 (*t*, C-1), 30.3 (*t*, C-2), 66.4 (*d*, C-3), 36.9 (*t*, C-4), 82.2 (*s*, C-5), 135.4 (*d*, C-6), 130.9 (*d*, C-7), 79.4 (*s*, C-8), 51.1 (*d*, C-9), 36.9 (*s*, C-10), 20.6 (*t*, C-11), 39.3 (*t*, C-12), 44.5 (*s*, C-13), 51.6 (*d*, C-14), 23.4 (*t*, C-15), 28.6 (*t*, C-16), 56.2 (*d*, C-17), 12.8 (*q*, C-18), 18.1 (*q*, C-19), 39.7 (*d*, C-20), 20.9 (*q*, C-21), 135.2 (*d*, C-22), 132.3 (*d*, C-23), 42.7 (*d*, C-24), 33.0 (*d*, C-25), 19.9 (*q*, C-26), 19.6 (*q*, C-27), 17.5 (*q*, C-28); EIMS: m/z 428 $[\text{M}]^+$.

Bassiatin; (3S, 6R-4-methyl-6-(1-methylethyl)-3-phenylmethyl-1, 4-perhydro-oxazine-2, 5-dione) (3) ¹²

Colorless crystals; mp 146-149°C; IR (KBr) ν max cm^{-1} 2960, 2920, 2895, 2860, 1745, 1645, 1490, 1450, 1440, 1405, 1360, 1330, 1320, 1250, 1030, 770, 700; $[\alpha]_D^{25} +176^\circ$ (*c* 0.5, chloroform); EIMS m/z : 261 $[\text{M}]^+$; HREIMS m/z : 261.1355 (calcd for $\text{C}_{15}\text{H}_{19}\text{NO}_3$, 261.1356)

X-ray Crystal Structure Analysis of Bassiatin (3)

A colorless orthorhombic crystal of **4** with dimensions 0.10 \times 0.25 \times 0.35mm was obtained by re-crystallization from ethyl acetate-hexane system and selected for X-ray analysis. The crystallographic data were collected on a Bruker Smart CCD diffractometer using graphite-monochromated Mo $\text{K}\alpha$ radiation. A structure analysis was made using the SHELXTL program on PC.¹⁴ The compound crystallized in the space group $P2_1$, $a = 10.0092(4)\text{ \AA}$, $b = 10.8521(4)\text{ \AA}$, $c = 13.1658(5)\text{ \AA}$, monoclinic, $V = 1430.08(9)\text{ \AA}^3$, $Z = 4$, $\text{Decal} = 1.214\text{ Mg/m}^3$, $\lambda = 0.71073\text{ \AA}$, $\mu(\text{Mo K}\alpha) = 0.084\text{ mm}^{-1}$, $F(000) = 560$, and $T = 296(2)\text{ K}$. A total of 10120 reflections were collected in the range of $2.43^\circ \leq \theta \leq 27.49^\circ$, of which

only 3275 unique reflections with $I > 2\sigma(I)$ were corrected for the analysis. The structure was solved using direct methods and refined by full-matrix-least-squares on F^2 values. Non-hydrogen atoms were refined anisotropically. Hydrogen atoms were fixed at calculated positions and refined using a riding mode. The final indices were $R = 0.0690$, $R_w = 0.1567$ with goodness-of-fit = 0.985. Scattering factors were taken from International Tables for X-ray Crystallography.¹⁵

Bassiatin A; (3S, 6R)-4-methyl-6-(1-methylpropyl)-3-phenylmethyl-1,4-perhydrooxazine-2,5-dione (4)

Colorless crystals; mp 145-147°C; $[\alpha]_D^{25} +187.5^\circ$ (c 0.038, dichloromethane); EIMS m/z : 275 $[M]^+$.

X-ray Crystal Structure Analysis of Bassiatin A (4)

A colorless monoclinic crystal of **4** with dimensions $0.40 \times 0.25 \times 0.10$ mm was obtained by re-crystallization from methanol-water system and selected for X-ray analysis. The crystallographic data were collected on a Bruker Smart CCD diffractometer using graphite-monochromated Mo $K\alpha$ radiation. A structure analysis was made using the SHELXTL program on PC.¹⁴ The compound crystallized in the space group $P2_1$, $a = 6.7580(3)$ Å, $b = 13.9359(6)$ Å, $c = 8.1205(4)$ Å, $\beta = 93.9460(10)^\circ$, monoclinic, $V = 762.97(6)$ Å³, $Z = Q$, $D_{\text{calc}} = 1.199$ Mg/m³, $\lambda = 0.71073$ Å, $\mu(\text{Mo } K\alpha) = 0.082$ mm⁻¹, $F(000) = 296$, and $T = 295(2)$ K. A total of 8037 reflections were collected in the range of $2.51^\circ \leq \theta \leq 27.50^\circ$, of which only 3490 unique reflections with $I > 2\sigma(I)$ were corrected for the analysis. The structure was solved using direct methods and refined by full-matrix-least-squares on F^2 values. Non-hydrogen atoms were refined anisotropically. Hydrogen atoms were fixed at calculated positions and refined using a riding mode. The final indices were $R = 0.0401$, $R_w = 0.1170$ with goodness-of-fit = 1.001. Scattering factors were taken from International Tables for X-ray Crystallography.¹⁵

Beauvericin (5)¹³

Colorless crystal; ¹H NMR (CDCl₃): δ 0.37 (3H, *d*, $J = 6.6$ Hz, γ 1-CH₃, Hiv), 0.76 (3H, *d*, $J = 6.6$ Hz, γ 2-CH₃, Hiv), 1.97 (1H, *m*, β -CH, Hiv), 2.93 (1H, *dd*, $J = 11.9, 14.5$ Hz, β -CH(*H*), Phe), 2.98 (3H, *s*, N-CH₃), 3.34 (1H, *dd*, $J = 4.9, 14.5$ Hz, β -CH(*H*), Phe), 4.89 (1H, *d*, $J = 8.5$ Hz, α -CH, Hiv), 5.51 (1H, *dd*, $J = 4.8, 11.8$ Hz, α -CH, Phe), 7.20 (5H, *ar* CH, Phe); ¹³C NMR (CDCl₃): δ 17.4 (*q*, γ 1-CH₃, Hiv), 18.2 (*q*, γ 2-CH₃, Hiv), 29.6 (*d*, β -CH, Hiv), 32.2 (*q*, N-CH₃), 34.7 (*t*, β -CH₂, Phe), 57.2 (*d*, α -CH, Phe), 75.4 (*d*, α -CH, Hiv), 126.7 (*d*, *ar* CH, Phe), 128.4 (*d*, *ar* CH, Phe), 128.8 (*d*, *ar* CH, Phe), 136.6 (*s*, *ar* C, Phe), 169.3 (*s*, CO), 169.8 (*s*, CO); HRFABMS m/z : $[M+H]^+$ 784.4164 (calcd for C₄₅H₅₈N₃O₉, 784.4173).

X-ray Crystal Structure Analysis of Beauvericin (5)

A colorless monoclinic crystal of **5** with dimensions $0.45 \times 0.40 \times 0.40$ mm was obtained by recrystallization from methanol-water system and selected for X-ray analysis. The crystallographic data were collected on a Bruker

Smart CCD diffractometer using graphite-monochromated Mo K α radiation. A structure analysis was made using the SHELXTL program on PC.¹⁴ The compound crystallized in the space group $P2_1$, $a = 8.3591(3)$ Å, $b = 17.1798(7)$ Å, $c = 15.9151(6)$ Å, $\beta = 93.084(1)^\circ$, monoclinic, $V = 2282.22(15)$ Å³, $Z = Q$, $D_{\text{calc}} = 1.240$ Mg/m³, $\lambda = 0.71073$ Å, μ (Mo K α) = 0.089mm⁻¹, $F(000) = 916$, and $T = 150$ K. A total of 24247 reflections was collected in the range of $1.28^\circ \leq \theta \leq 27.50^\circ$, of which only 10466 unique reflections with $I > 2\sigma(I)$ were corrected for the analysis. The structure was solved using direct methods and refined by full-matrix-least-squares on F^2 values. Non-hydrogen atoms were refined anisotropically. Hydrogen atoms were fixed at calculated positions and refined using a riding mode. The final indices were $R = 0.045$, $R_w = 0.122$ with goodness-of-fit = 1.046. Scattering factors were taken from International Tables for X-ray Crystallography.¹⁵

Beauvericin A (6)¹³

Colorless crystal; ¹H NMR (CDCl₃): δ 0.39 (3H, *d*, $J = 6.7$ Hz, $\gamma 1$ -CH₃, Hiv), 0.40 (3H, *d*, $J = 6.8$ Hz, $\gamma 1$ -CH₃, Hiv), 0.65 (3H, *m*, δ -CH₃, Hmp), 0.70 (2H, *m*, $\gamma 1$ -CH₂, Hmp), 0.74 (3H, *d*, $J = 6.5$ Hz, $\gamma 2$ -CH₃, Hiv), 0.76 (3H, *d*, $J = 6.7$ Hz, $\gamma 2$ -CH₃, Hiv), 0.78 (3H, *d*, $J = 6.9$ Hz, $\gamma 2$ -CH₃, Hmp), 1.77 (1H, *m*, β -CH, Hmp), 2.02 (2H, *m*, β -CH, Hiv), 2.95 (3H, *s*, N-CH₃), 2.99 (6H, *s*, N-CH₃), 2.90~2.99 (3H, β -CH(*H*), Phe), 3.34 (3H, β -CH(*H*), Phe), 4.87 (1H, *d*, $J = 8.6$ Hz, α -CH, Hiv), 4.89 (1H, *d*, $J = 8.4$ Hz, α -CH, Hiv), 4.98 (1H, *d*, $J = 7.7$ Hz, α -CH, Hmp), 5.50 (3H, *m*, α -CH, Phe), 7.20 (15H, *m*, ar CH, Phe); ¹³C NMR (CDCl₃): δ 11.3 (δ -CH₃, Hmp), 14.4 ($\gamma 2$ -CH₃, Hmp), 17.4 ($\gamma 1$ -CH₃, Hiv), 18.3 ($\gamma 2$ -CH₃, Hiv), 24.3 ($\gamma 1$ -CH₂, Hmp), 29.7 (β -CH, Hiv), 32.1 (N-CH₃), 32.1 (N-CH₃), 34.6 (β -CH₂, Phe), 34.8 (β -CH₂, Phe), 35.9 (β -CH, Hmp), 57.1 (α -CH, Phe), 57.2 (α -CH, Phe), 74.3 (α -CH, Hmp), 75.5 (α -CH, Hiv), 126.7 (ar CH, Phe), 128.4 (ar CH, Phe), 128.8 (ar CH, Phe), 136.6 (ar C, Phe), 169.5 (CO), 169.9 (CO); HRFABMS m/z [M+H]⁺ 798.4332 (calcd for C₄₆H₆₀N₃O₉, 784.4330).

X-ray Crystal Structure Analysis of Beauvericin A (6)

A colorless monoclinic crystal of **6** with dimensions 0.45 × 0.40 × 0.13mm was obtained by re-crystallization from methanol-water system and selected for X-ray analysis. The crystallographic data were collected on a Bruker Smart CCD diffractometer using graphite-monochromated Mo K α radiation. A structure analysis was made by using the SHELXTL program on PC.¹⁴ The compound crystallized in the space group $P2_1$, $a = 8.4078(4)$ Å, $b = 17.0702(7)$ Å, $c = 16.4296(10)$ Å, $\beta = 92.947(1)^\circ$, monoclinic, $V = 2341.60(19)$ Å³, $Z = Q$, $D_{\text{calc}} = 1.228$ Mg/m³, $\lambda = 0.71073$ Å, μ (Mo K α) = 0.088mm⁻¹, $F(000) = 932$, and $T = 150$ (2) K. A total of 20829 reflections was collected in the range of $1.25^\circ \leq \theta \leq 27.50^\circ$, of which only 9936 unique reflections with $I > 2\sigma(I)$ were corrected for the analysis. The structure was solved using direct methods and refined by full-matrix-least-squares on F^2 values. Non-hydrogen atoms were refined anisotropically. Hydrogen atoms were fixed at calculated positions and refined using a riding mode. The final

indices were $R = 0.0614$, $R_w = 0.1362$ with goodness-of-fit = 1.034. Scattering factors were taken from International Tables for X-ray Crystallography.¹⁵

Beauvericin B (7)¹³

Colorless crystal; ¹H NMR (CDCl₃): δ 0.38 (3H, *d*, $J = 6.6\text{Hz}$, $\gamma 1\text{-CH}_3$, Hiv), 0.65 (6H, *m*, $\delta\text{-CH}_3$, and 4H, *m*, $\gamma 1\text{-CH}_2$, Hmp), 0.73 (3H, *d*, $J = 6.7\text{Hz}$, $\gamma 2\text{-CH}_3$, Hiv), 0.75 (3H, *d*, $J = 7.0\text{Hz}$, $\gamma 2\text{-CH}_3$, Hmp), 0.76 (3H, *d*, $J = 6.5\text{Hz}$, $\gamma 2\text{-CH}_3$, Hiv), 1.62 (2H, *m*, $\beta\text{-CH}$, Hmp), 1.93 (1H, *m*, $\beta\text{-CH}$, Hiv), 2.96 (6H, *s*, N-CH₃), 2.99 (3H, *s*, N-CH₃), 2.87~3.02 (3H, *m*, $\beta\text{-CH}(H)$, Phe), 3.37 (3H, *m*, $\beta\text{-CH}(H)$, Phe), 4.84 (1H, *d*, $J = 8.1\text{Hz}$, $\alpha\text{-CH}$, Hiv), 4.94 (1H, *d*, $J = 7.5\text{Hz}$, $\alpha\text{-CH}$, Hmp), 4.95 (1H, *d*, $J = 7.3\text{Hz}$, $\alpha\text{-CH}$, Hmp), 5.57 (3H, *m*, $\alpha\text{-CH}$, Phe), 7.21(15H, *m*, ar CH, Phe); HRFABMS m/z [M+H]⁺ 812.4492 (calcd for C₄₇H₆₂N₃O₉, 812.4486).

ACKNOWLEDGMENT

The authors thank the National Science Council of the Republic of China for financial support (NSC 89-2113-M-077-007), and Dr. Tun-Tschu Chang for the identification of *C. cicadae*.

REFERENCES

1. Juangsu New Medical College. Zhong Yao Da Ci Dian (Dictionary Chinese Materia Medica), Shanghai Scientific and Technological Publishers, Shanghai, pp. 2557-2558, 1979.
2. Ukai S, Matsuura S, Hara C, Kiho T, Hirose K. Polysaccharides in fungi. Part VII. Structure of a new galactomannan from the ascocarps of *Cordyceps cicadae* Shing. Carbohydr Res 101: 109-116, 1982.
3. Ukai S, Kiho T, Hara C, Morita M, Goto A, Imaizumi N, Hasegawa Y. Polysaccharides in fungi. VIII. Antitumor activity of various polysaccharides isolated from *Dictyophora indusiata*, *Ganoderma japonicum*, *Cordyceps cicadae*, *Auricularia auricula-judae*, and *Auricularia* species. Chem Pharm Bull 31: 741-744, 1983.
4. Kiho T, Miyamoto I., Nagai K, Ukai S, Hara C. Polysaccharides in fungi. Part XXI. Minor, protein-containing galactomannans from the insect-body portion of the fungal preparation Chan hua (*Cordyceps cicadae*). Carbohydr Res 181: 207-215, 1988. Chemical Abstract 109: 186925c, 1988.
5. Kiho T, Ito M, Nagai K, Hara C, Ukai S. Polysaccharides in fungi XXII. A water-soluble polysaccharide from the alkaline extract of the insect-body portion of chan-hua (fungus: *Cordyceps cicadae*). Chem Pharm Bull. 36: 3032-3037, 1988.
6. Kiho T, Ito M, Yoshida I, Nagai K, Hara C, Ukai S. Polysaccharides in fungi. XXIV. A (1-3)- β -D-glucan from the alkaline extract of the insect-body portion of chan hua (fungus: *Cordyceps cicadae*). Chem Pharm Bull 37: 2770-2772, 1989.
7. Kiho T, Nagai K, Miyamoto I., Watanabe T, Ukai S. Polysaccharides in fungi. XXV. Biological activities

- of two galactomannans from the insect-body portion of chan hua (fungus: *Cordyceps cicadae*). *Yakugaku Zasshi* 110: 286-288, 1990.
8. Weng SC, Chou CJ, Lin LW, Tsai WJ, Kuo YC. Immunomodulatory functions of extracts from the Chinese medicinal fungus *Cordyceps cicadae* *J Ethnopharmacology* 2002. in press.
 9. Takaishi Y, Uda M, Ohashi T, Nakano K, Murakami K, Tomimatsu T. Glycosides of ergosterol derivatives from *Hericum erinacens*. *Phytochemistry* 30: 4117-4120, 1991.
 10. Sgarbi DBG, Silva AJR, Carlos IZ, Silva CL, Angluster J, Alviano CS. Isolation of ergosterol peroxide and its reversion to ergosterol in the pathogenic fungus *Sporothrix schenckii*. *Mycopathologia* 139: 9-14, 1997.
 11. Bok JW, Lermer L, Chilton J, Klingeman HG, Neil Towers GH. Antitumor sterols from the mycelia of *Cordyceps sinensis*. *Phytochemistry* 51: 891-898, 1999.
 12. Kagamizono T, Nishino E, Matsumoto K, Kawashima A, Kishimoto M, Sakai N, He BM, Chen Z. X, Adachi T, Morimoto S, Hanada K. Bassiatin, a new platelet aggregation inhibitor produced by *Beauveria bassiana* K-717. *J Antibiotics* 48: 1407-1412, 1995.
 13. Gupta S, Montllor, Hwang YS. Isolation of novel beauvericin analogues from the fungus *Beauveria bassiana*. *J Nat Prod* 58: 733-738, 1995.
 14. Sheldrick GM. SHELXTL/PC, Version 5.10, Bruker Analytical X-ray Instruments Inc., Madison, WI. 1997.
 15. Ibers, J. A., Hamilton, W.C. (eds), *International Tables for X-ray Crystallography*, The Kynoch Press: Birmingham, U. K., Vol. IV, 1974.

J Chin Med 13(4): 209-219, 2002

中藥蟬花活性成分之研究

郭育綺^{1,2} 林麗純¹ 董明兆¹ 廖慧芬¹ 蔡雨萍¹ 李錦祥³ 周正仁¹

¹國立中國醫藥研究所

²輔仁大學生命科學研究所

³國立台灣大學理學院儀器中心

台北

(2002年9月19日受理, 2002年10月4日收校訂稿, 2002年10月11日接受刊載)

中藥蟬花是麥角菌科(Clavicipitaceae)大草蟬草菌(*Cordyceps cicadae* Shing)寄生在山蟬(*Cicada flammata* Dist)幼蟲的真菌, 藥材包括其子實體及蟲體, 是作為治療小兒驚厥, 心悸, 及鎮定的中藥。在我們擬由天然物中覓找生理活性物質的系列, 發現其蟲體甲醇提取物在植物凝集素(DHA)刺激下, 呈現抑制人類單核細胞增生活性, 其抑制度與濃度成比例關係, 因此, 進行其活性成分之探研, 經本次實驗研究, 蟬花蟲體部份離出麥角甾醇(ergosterol), 過氧麥角甾醇(ergosterol peroxide), 白僵菌酮(bassiatin)及白僵菌酮甲(bassiatin A), 白僵菌素(beauvericin), 白僵菌素甲(beauvericin A), 白僵菌素乙(beauvericin B), 後五個成分環酯 抗生素及嗎 二酮, 係首次從中藥蟬花獲得, 其中白僵菌酮甲(bassiatin A)更是首次由天然物界發現。

關鍵詞：蟬花, 真菌, 甾醇, 環酯 化合物, 嗎 二酮化合物。